Clinical Scorecard: Outcomes of Gamma Knife Radiosurgery for Brain Metastases from Renal Cell Carcinoma Across Different Systemic Treatment Periods: Survival Rates, Intracranial Progression, and Predictive Factors at the Lesion Level
At a Glance
Category
Detail
Condition
Renal Cell Carcinoma Brain Metastases
Key Mechanisms
Gamma Knife radiosurgery (GKRS) for local control of brain metastases.
Target Population
Patients with intracranial metastases from renal cell carcinoma.
Care Setting
Retrospective cohort study evaluating treatment outcomes.
Key Highlights
RCC accounts for approximately 90% of kidney malignancies.
Brain metastases occur in roughly 4–11% of RCC cases.
Stereotactic radiosurgery (SRS) is a preferred treatment modality.
Systemic therapy has evolved with TKIs and ICIs as foundational components.
Integration of systemic therapy with SRS may improve outcomes.
Guideline-Based Recommendations
Diagnosis
Intracranial RCC metastases diagnosed via imaging and clinical assessment.
Management
Local therapy including surgical resection and GKRS for symptomatic lesions.
Monitoring & Follow-up
Follow-up with clinical assessments and MRI at standardized intervals.
Risks
Potential toxicity such as radiation necrosis with combined therapies.
Patient & Prescribing Data
34 patients with 87 intracranial lesions treated with GKRS.
Systemic therapy categorized as TKI only, IO only, TKI plus IO, or no systemic therapy.
Clinical Best Practices
Individualized prescription dose and plan parameters based on lesion characteristics.
Consideration of extracranial disease burden when planning treatment.
by Neil D. Almeida, Sarthak Sinha, Mengyu Fang, Harshini Cheruvu, Roshan Tasgaonkar, Babar Gulzar, Venkatesh Madhugiri, Victor Goulenko, Dheerendra Prasad
